No Data
Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
J.P. Morgan Maintains Stoke Therapeutics(STOK.US) With Hold Rating, Raises Target Price to $15
Express News | Stoke Therapeutics Shares Are Trading Higher on Possible Continued Strength Following Q3 Reported Financial Results Yesterday. Also, Needham and HC Wainwright & Co. Reiterated Buy Ratings on the Stock
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $15 to $35
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
